Bekymringerne for HepB- komponentens immunogenicitet voksede, da der blev observeret lavere serokonversionsrater end forventet efter samtidig administration af Hexavac og andre meningokok - og pneumokokvacciner.
The concerns over the immunogenicity of the HepB component increased when lower than expected seroconversion rates were observed following the concomitant administration of Hexavac with other meningococcal and pneumococcal vaccines.